ClinicalTrials.gg
CompletedNCT04819438Updated May 2, 2025Results posted

Riluzole Orodispersible Film Replicate Bioavailability

A Phase 1 interventional study of Riluzole 50 mg orodispersible film and Rilutek® 50 mg riluzole tablets in Healthy Participants, sponsored by Cross Research S.A.. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by Cross Research S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of the study is to compare the pharmacokinetic profile of riluzole after replicate single dose of the novel orodispersible film test formulation and of the marketed reference Rilutek® tablets and to evaluate their bioequivalence.

Read the detailed description

The new formulation riluzole orodispersible film is expected to fill an important medical need, since the medication can be easily administered without water and may improve patient care. Riluzole orodispersible film is easily administered, because the patient or caregiver needs only to place the film on the tongue, where it can immediately dissolve into the saliva and be ingested with intentional swallowing or during the normal reflex of swallowing, thus eliminating the need for swallowing a tablet with liquid or crushing it into soft food.

Zambon S.p.A., Italy, is sponsoring the present bioequivalence study in order to investigate the bioequivalence of the novel unit-dose product versus Rilutek® tablets, commercially available in Europe as 50 mg tablets. The dose strength for the test formulation is 50 mg, matching the 50 mg strength of the reference formulation.

The subjects will receive single oral doses of 50 mg of riluzole, as test orodispersible film and reference film-coated tablets, under fasting conditions, in each of 4 subsequent periods separated by wash-out intervals of at least 7 days between consecutive administrations, according to a 2-treatment, 4-period, replicate cross-over design.

02

Conditions studied

  • Healthy Participants

Keywords

  • Bioequivalence
  • Riluzole
  • Orodispersible film
03

In context

Lead sponsor

Cross Research S.A. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. : signed written informed consent before inclusion in the study
  2. Sex and Age: men/women, 18-55 years old inclusive
  3. Tobacco: non-smokers for at least 6 months prior to study screening
  4. (BMI): 18.5-29 kg/m2 inclusive
  5. Vital signs: systolic blood pressure (SBP) 100-139 mmHg, diastolic blood pressure (DBP) 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position
  6. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study
  7. and fertility (women only): women of must be using at least one of the following reliable methods of contraception:

    1. A non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit
    2. A male sexual partner who agrees to use a male condom with spermicide
    3. A sterile sexual partner Female participants of non-child-bearing potential or in status for at least 1 year will be admitted. For all women, pregnancy test result must be negative at screening.

Exclusion criteria

Exclusion Criteria:

  1. (ECG) 12-leads: (supine position) abnormalities; interval > 450 msec
  2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study
  3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness
  4. Cotinine: positive cotinine test at screening
  5. Allergy: ascertained or presumptive to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study
  6. Diseases: clinically significant history or presence of renal, hepatic, gastrointestinal, cardiovascular, cerebrovascular, immunological, musculoskeletal, respiratory, skin, haematological, endocrine, psychiatric or neurological diseases or surgeries that may interfere with the aim of the study. Gastrointestinal pathologies include any clinically significant disorder of the mouth, e.g. impairment of swallowing, lesions, ulcerations, deformities, untreated dental caries
  7. Dentures: presence of mouth jewellery, dentures, braces, piercings that may interfere with successful completion of the dosing
  8. Medications: medications, including over the counter medications and herbal remedies for 2 weeks before study screening; central nervous system depressants, including opioids, benzodiazepines, general anaesthetics and anticonvulsants, or cytochrome C inhibitors, including cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and antiretroviral agents, or strong cytochrome C inducers, including barbiturates, carbamazepine, , phenytoin, St John's wort and rifampin, or hormonal oral or transdermal for 30 days before study screening; implanted, injected, intravaginal or intrauterine hormonal contraceptives for 6 months before study screening
  9. Investigative drug studies: participation in the evaluation of any product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
  10. Blood donation: blood donations for 3 months before this study
  11. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>1 drink/day for females and >2 drinks/day for males, defined according to the Dietary Guidelines 2015 ], caffeine (>5 cups coffee/tea/day) or tobacco use including any tobacco product like e-cigarettes and vamping products
  12. Drug test: positive result at the drug test at screening or Day -1
  13. Alcohol test: positive alcohol breath test at Day -1
  14. Diet: abnormal diets (\<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians and vegans
  15. Pregnancy (women only): positive or missing pregnancy test at screening or Day -1, pregnant or lactating women
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Reference/Test/Reference/Test

    Riluzole orodispersible film (test): The subjects will be treated with one orodispersible film containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence Rilutek® (reference): The subjects will be treated with one film-coated tablet containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence.

    Drug: Riluzole 50 mg orodispersible film · Drug: Rilutek® 50 mg riluzole tablets

  • Experimental
    Test/Reference/Test/Reference

    Riluzole orodispersible film (test): The subjects will be treated with one orodispersible film containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence Rilutek® (reference): The subjects will be treated with one film-coated tablet containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence.

    Drug: Riluzole 50 mg orodispersible film · Drug: Rilutek® 50 mg riluzole tablets

Interventions

  • Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.

    Also known as: Test product (T)

  • One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.

    Also known as: Reference product (R)

06

What researchers measure

Primary outcomes

  1. Evaluation of the Bioequivalent Rate of Absorption (Cmax) of Riluzole After Replicate Single Dose Administration of Test and Reference

    For each individual, the maximum plasma concentration (Cmax) of riluzole after replicate single dose administration of Test and Reference was measured. The Cmax 90% confidence interval of the ratio Test/Reference of the population means was calculated. The bioequivalence is demonstrated when the 90% confidence Interval of this ratio lies within the range 80.00-125.00% (acceptance interval).

    Time frame: 0 h (pre-dose) and 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after the drug administration

  2. Evaluation of the Bioequivalent Extent of Absorption (AUC0-t) of Riluzole After Replicate Single Dose Administration of Test and Reference.

    For each individual, the area under the concentration-time curve from single dose Test and Reference administration to the last observed concentration time t (AUC0-t) of riluzole was measured. The AUC0-t 90% confidence interval of the ratio Test/Reference of the population means was calculated. The bioequivalence is demonstrated when the 90% confidence Interval of this ratio lies within the range 80.00-125.00% (acceptance interval).

    Time frame: 0 h (pre-dose), 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after drug administration

Secondary outcomes

  1. To Describe the t1/2 (Half-life) of Riluzole After Replicate Single Dose Administration of Test and Reference

    To Describe the half-life of riluzole, calculated, if feasible, as ln2/λz, After Replicate Single Dose Administration of Test and Reference.

    Time frame: 0 h (pre-dose), 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after drug administration

  2. To Describe the AUC0-∞ of Riluzole After Replicate Single Dose Administration of Test and Reference

    For each individual, the area under the concentration-time curve extrapolated to infinity after single dose administration of Test and Reference (AUC0-∞) was measured. The AUC0-∞ 90% confidence interval of the ratio Test/Reference of the population means was calculated. The bioequivalence is demonstrated when the 90% confidence Interval of this ratio lies within the range 80.00-125.00% (acceptance interval).

    Time frame: 0 h (pre-dose), 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after drug administration

  3. Description Tmax: Time to Achieve Cmax Reference

    The results will be displayed and summarised in tables and figures.

    Time frame: 0 h (pre-dose), 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after drug administration

  4. Evaluation of the Test Product Palatability

    Palatability was scored according to the following scale. Palatability evaluation description and scores (between brackets): Very unpleasant (0), Unpleasant (1), Acceptable (2), Good (3), Very good (4). Minimun value is 0, maximum value is 4. An higher score mean a better outcome.

    Time frame: Immediately after 1st Test product administration, approximately within 5 minutes after administration

  5. Evaluation of the Test Product Palatability

    Palatability was scored according to the following scale. Palatability evaluation description and scores (between brackets): Very unpleasant (0), Unpleasant (1), Acceptable (2), Good (3), Very good (4). Minimun value is 0, maximum value is 4. An higher score mean a better outcome.

    Time frame: Immediately after 2nd Test product administration, approximately within 5 minutes after administration

  6. Number of Participants With Mucosal Irritation

    Mouth inspections were performed before the Test administration and 30 min and 1 h after administrations of Test, to check the mucosal irritation at the application site. The outcome number shows the overall number of subjects with mucosal irritation.

    Time frame: pre-dose (0), 0.5 and 1 h after the drug administration

  7. Haematology, Blood Chemistry and Urinalysis Laboratory Tests Interpretation

    Overall investigator's interpretation (as normal or abnormal and, if abnormal, clinically significant or not clinically significant). The following analyses were performed at screening: Leukocytes, erythrocytes, haemoglobin, haematocrit, MCV, MCH, MCHC, thrombocytes, electrolytes, enzymes (alkaline phosphatase, γ-GT, AST, ALT), total bilirubin, creatinine, glucose, urea, uric acid, total cholesterol, triglycerides, cotinine, total proteins. Serum pregnancy test (women). Urine analysis: pH, specific weight, appearance, colour, nitrites, proteins, glucose, urobilinogen, bilirubin, ketones, haematic pigments, leukocytes. Urine sediment (analysis performed only if positive): leukocytes, erythrocytes, flat cells, round cells, crystals, cylinders, mucus, bacteria. Hepatitis B (HBs antigen), Hepatitis C (HCV antibodies), HIV 1/2 (HIV Ag/Ab combo). The same analyses, with the exception of cotinine, urine drug test, virology and pregnancy test, were performed at the final visit

    Time frame: At screening (initial visit) and at final visit (approximately 1 month)

07

Results

Posted May 2, 2025

Participant flow

Participants were recruited at the Phase I Unit from January 2021 to February 2021.

Participant flow — Overall Study
MilestoneRiluzole 50mg (Test) / Rilutek 50mg (Reference) / Riluzole 50mg (Test) / Rilutek 50mg (Reference)Rilutek 50mg (Reference) / Riluzole 50mg (Test) / Rilutek 50mg (Reference) / Riluzole 50mg (Test)
Started2727
Completed2625
Not completed12
Withdrew: Withdrawal by subject10
Withdrew: Adverse event01
Withdrew: Protocol violation01

Outcome measures

PrimaryEvaluation of the Bioequivalent Rate of Absorption (Cmax) of Riluzole After Replicate Single Dose Administration of Test and Reference

For each individual, the maximum plasma concentration (Cmax) of riluzole after replicate single dose administration of Test and Reference was measured. The Cmax 90% confidence interval of the ratio Test/Reference of the population means was calculated. The bioequivalence is demonstrated when the 90% confidence Interval of this ratio lies within the range 80.00-125.00% (acceptance interval).

Time frame:
0 h (pre-dose) and 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after the drug administration
Reported as:
Mean · ng/mL
Evaluation of the Bioequivalent Rate of Absorption (Cmax) of Riluzole After Replicate Single Dose Administration of Test and Reference
ng/mLRiluzole Orodispersible Film (Test)Rilutek® Tablet (Reference)
Evaluation of the Bioequivalent Rate of Absorption (Cmax) of Riluzole After Replicate Single Dose Administration of Test and Reference315.62 ± 124.95278.81 ± 123.32
Statistical analysis
  • Riluzole Orodispersible Film (Test) vs Rilutek® Tablet (Reference) · ANOVA · p = <0.0001 · Geometric mean ratio: 117.05 · 90% CI 110.43 to 124.06
PrimaryEvaluation of the Bioequivalent Extent of Absorption (AUC0-t) of Riluzole After Replicate Single Dose Administration of Test and Reference.

For each individual, the area under the concentration-time curve from single dose Test and Reference administration to the last observed concentration time t (AUC0-t) of riluzole was measured. The AUC0-t 90% confidence interval of the ratio Test/Reference of the population means was calculated. The bioequivalence is demonstrated when the 90% confidence Interval of this ratio lies within the range 80.00-125.00% (acceptance interval).

Time frame:
0 h (pre-dose), 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after drug administration
Reported as:
Mean · h*ng/mL
Evaluation of the Bioequivalent Extent of Absorption (AUC0-t) of Riluzole After Replicate Single Dose Administration of Test and Reference.
h*ng/mLRiluzole Orodispersible Film (Test)Rilutek® Tablet (Reference)
Evaluation of the Bioequivalent Extent of Absorption (AUC0-t) of Riluzole After Replicate Single Dose Administration of Test and Reference.1263.40 ± 571.581135.98 ± 514.98
Statistical analysis
  • Riluzole Orodispersible Film (Test) vs Rilutek® Tablet (Reference) · ANOVA · p = <0.0001 · Geometric mean ratio: 111.82 · 90% CI 108.25 to 115.50
SecondaryTo Describe the t1/2 (Half-life) of Riluzole After Replicate Single Dose Administration of Test and Reference

To Describe the half-life of riluzole, calculated, if feasible, as ln2/λz, After Replicate Single Dose Administration of Test and Reference.

Time frame:
0 h (pre-dose), 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after drug administration
Reported as:
Mean · h
To Describe the t1/2 (Half-life) of Riluzole After Replicate Single Dose Administration of Test and Reference
hRiluzole Orodispersible Film (Test)Rilutek® Tablet (Reference)
To Describe the t1/2 (Half-life) of Riluzole After Replicate Single Dose Administration of Test and Reference10.22 ± 1.6610.22 ± 1.48
SecondaryTo Describe the AUC0-∞ of Riluzole After Replicate Single Dose Administration of Test and Reference

For each individual, the area under the concentration-time curve extrapolated to infinity after single dose administration of Test and Reference (AUC0-∞) was measured. The AUC0-∞ 90% confidence interval of the ratio Test/Reference of the population means was calculated. The bioequivalence is demonstrated when the 90% confidence Interval of this ratio lies within the range 80.00-125.00% (acceptance interval).

Time frame:
0 h (pre-dose), 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after drug administration
Reported as:
Mean · h*ng/mL
To Describe the AUC0-∞ of Riluzole After Replicate Single Dose Administration of Test and Reference
h*ng/mLRiluzole Orodispersible Film (Test)Rilutek® Tablet (Reference)
To Describe the AUC0-∞ of Riluzole After Replicate Single Dose Administration of Test and Reference1348.31 ± 630.801207.79 ± 566.13
Statistical analysis
  • Riluzole Orodispersible Film (Test) vs Rilutek® Tablet (Reference) · ANOVA · p = <0.0001 · Geometric mean ratio: 111.83 · 90% CI 108.19 to 115.29
SecondaryDescription Tmax: Time to Achieve Cmax Reference

The results will be displayed and summarised in tables and figures.

Time frame:
0 h (pre-dose), 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after drug administration
Reported as:
Median · h
Description Tmax: Time to Achieve Cmax Reference
hRiluzole Orodispersible Film (Test)Rilutek® Tablet (Reference)
Description Tmax: Time to Achieve Cmax Reference0.75 (0.25 to 2)0.75 (0.25 to 4)
SecondaryEvaluation of the Test Product Palatability

Palatability was scored according to the following scale. Palatability evaluation description and scores (between brackets): Very unpleasant (0), Unpleasant (1), Acceptable (2), Good (3), Very good (4). Minimun value is 0, maximum value is 4. An higher score mean a better outcome.

Time frame:
Immediately after 1st Test product administration, approximately within 5 minutes after administration
Reported as:
Count of participants · Participants
Evaluation of the Test Product Palatability
ParticipantsRiluzole Orodispersible Film (Test)
0 - very unpleasant0
1 - unpleasant1
2 - acceptable15
3 - good31
4 - very good5
SecondaryEvaluation of the Test Product Palatability

Palatability was scored according to the following scale. Palatability evaluation description and scores (between brackets): Very unpleasant (0), Unpleasant (1), Acceptable (2), Good (3), Very good (4). Minimun value is 0, maximum value is 4. An higher score mean a better outcome.

Time frame:
Immediately after 2nd Test product administration, approximately within 5 minutes after administration
Reported as:
Count of participants · Participants
Evaluation of the Test Product Palatability
ParticipantsRiluzole Orodispersible Film (Test)
0 - very unpleasant0
1 - unpleasant2
2 - acceptable14
3 - good28
4 - very good7
SecondaryNumber of Participants With Mucosal Irritation

Mouth inspections were performed before the Test administration and 30 min and 1 h after administrations of Test, to check the mucosal irritation at the application site. The outcome number shows the overall number of subjects with mucosal irritation.

Time frame:
pre-dose (0), 0.5 and 1 h after the drug administration
Reported as:
Count of participants · Participants
Number of Participants With Mucosal Irritation
ParticipantsRiluzole Orodispersible Film (Test)
Number of Participants With Mucosal Irritation0
SecondaryHaematology, Blood Chemistry and Urinalysis Laboratory Tests Interpretation

Overall investigator's interpretation (as normal or abnormal and, if abnormal, clinically significant or not clinically significant). The following analyses were performed at screening: Leukocytes, erythrocytes, haemoglobin, haematocrit, MCV, MCH, MCHC, thrombocytes, electrolytes, enzymes (alkaline phosphatase, γ-GT, AST, ALT), total bilirubin, creatinine, glucose, urea, uric acid, total cholesterol, triglycerides, cotinine, total proteins. Serum pregnancy test (women). Urine analysis: pH, specific weight, appearance, colour, nitrites, proteins, glucose, urobilinogen, bilirubin, ketones, haematic pigments, leukocytes. Urine sediment (analysis performed only if positive): leukocytes, erythrocytes, flat cells, round cells, crystals, cylinders, mucus, bacteria. Hepatitis B (HBs antigen), Hepatitis C (HCV antibodies), HIV 1/2 (HIV Ag/Ab combo). The same analyses, with the exception of cotinine, urine drug test, virology and pregnancy test, were performed at the final visit

Time frame:
At screening (initial visit) and at final visit (approximately 1 month)
Reported as:
Count of participants · Participants
Haematology, Blood Chemistry and Urinalysis Laboratory Tests Interpretation
ParticipantsRiluzole Orodispersible Film (Test) / Rilutek® Tablet (Reference)
Screening visit — Normal3
Screening visit — Abnormal, Not Clinically Significant50
Screening visit — Abnormal, Clinically Significant0
Final visit (approximately 1 month) — Normal1
Final visit (approximately 1 month) — Abnormal, Not Clinically Significant52
Final visit (approximately 1 month) — Abnormal, Clinically Significant0

Adverse events

Collected over 36 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Riluzole Orodispersible Film (Test)0/52 (0%)0/52 (0%)52/52 (100%)
Rilutek® (Reference)0/53 (0%)0/53 (0%)14/53 (26.4%)
Most frequent other events
Most frequent other events
EventRiluzole Orodispersible Film (Test)Rilutek® (Reference)
Hypoaesthesia oralGastrointestinal disorders52/520/53
HeadacheNervous system disorders11/5214/53

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Study Participants
Mean40.3 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female33
Male21
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White51
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)All Study Participants
Switzerland54
Body weight
Body weight(kilograms)All Study Participants
Mean65.86 ± 10.87
Height
Height(centimeters)All Study Participants
Mean167.8 ± 8.9
Body mass index
Body mass index(kilograms/square meters)All Study Participants
Mean23.30 ± 2.65
08

Study locations

1 site
  • CROSS Research SA Phase 1 Unit
    Arzo, Ticino 6864, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Mar 2021, 1 month.

Results were first posted in May 2025, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2021
First posted
Mar 29, 2021
StartActual
Jan 15, 2021
Primary completionActual
Mar 14, 2021
CompletionActual
Mar 14, 2021
Results first posted
May 2, 2025
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04819438
Lead sponsor
Cross Research S.A.
Collaborators
Zambon SpA
Responsible party
Milko Radicioni (Principal Investigator, Cross Research S.A.) — Principal investigator
First posted
Mar 29, 2021
Start date
Jan 15, 2021
Primary completion
Mar 14, 2021
Completion
Mar 14, 2021
Results posted
May 2, 2025
Last update
May 2, 2025

Study contacts

Milko Radicioni, MD
principal investigator · CROSS Research SA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riluzole

Start the discussion